Current clinical guidelines recommend avoiding GLP-1 medications while breastfeeding and waiting until lactation has completely ended before starting or resuming treatment
This threefold activity has been associated with significant weight loss (up to 24% of body weight in 6 months) in clinical trials
Patients may benefit from a structured protein target based on body size, goal weight, kidney function, activity level, and medical history
What the Research Says About SSRIs and GLP-1 Together A 2022 analysis published in Diabetes, Obesity and Metabolism examined GLP-1 receptor agonist use in patients with comorbid depression and found that semaglutide treatment was not associated with worsening depressive symptoms
Hallazgos preclnicos en roedores: hiperplasia de clulas C tiroideas (comn a todos los agonistas GLP-1 prolongados), por lo que los protocolos en roedores monitorizan histologa tiroidea terminal
Consistent communication via phone, portal messages, or telehealth visits keeps patients accountable across all their chronic conditions, not just weight loss or glycemic control
